Impact of COVID-19 on patients with metastatic breast cancer: REthink Access to Care and Treatment survey results.
Neil M IyengarClay WilliamsMichael RoganLaurie CampbelShirley MertzJeremy BlockMaria EblingConnie ChenJustin DoanSamantha K KuroskyTimothy J PluardPublished in: Future oncology (London, England) (2024)
Aim: Patients with metastatic breast cancer (MBC) may be vulnerable to changes in healthcare management, safety standards and protocols that occurred during the COVID-19 pandemic. Materials & methods: The REthink Access to Care & Treatment (REACT) survey assessed USA-based patient perspectives on COVID-19-related impacts to their MBC treatment experience between 27 April 2021 and 17 August 2021. Results: Participants (n = 341; 98.5% females, mean age 50.8 years) reported that overall oncology treatment quality was maintained during the pandemic. Delayed/canceled diagnostic imaging was reported by 44.9% of participants while telemedicine uptake was high among participants (80%). Conclusion: Overall, MBC care was minimally affected by the pandemic, possibly due to the expanded use of telemedicine, informing MBC management for future public health emergencies.